|
|
|
市場調査レポート
世界のホルモン補充療法とその他のホルモン療法市場
Hormone Replacement Therapies and Other Hormone Therapies: Global Markets
|
Abstract
This report:
- Describes the hormone replacement therapy (HRT) for different conditions
including menopause, cancer, Growth Hormone deficiency, Turner' s Syndrome,
Klinfelter' s Syndrome, osteoporosis and Alzheimer' s disease
- Includes a current market analysis and five-year market projections, from
2008 to 2013
- Discusses regulatory issues including new drug approvals
- Provides complete company profiles, competitive analysis, industry
structure, market shares, and patent analyses.
SCOPE OF REPORT
The scope of this study encompasses global markets for hormonal therapies. BCC
analyzes each market and its market leaders; different types of therapies; the
regulatory environment; the different disease sectors for the use of hormonal
therapies; and market projections and market share. Technological issues
include the latest trends and new developments.
METHODOLOGY
A comprehensive literature search was conducted. The literature included
technical newsletters and journals as well as many other sources. Data were
collected through interviews and correspondence with various
pharmaceutical/biotechnical experts. Projections were based on estimates such
as the current number of end users, potential end users, likely unit prices,
rates of consumption, and market trends.
INFORMATION SOURCES
BCC surveyed many companies to obtain data for this study. Included were
manufacturers and the end users of the cancer drugs. We gathered the data from
the industries; spoke with officials of this industry; and consulted
newsletters, company literature, product literature, a host of technical
articles, journals, indexes, and abstracts. Exhaustive investigations of
databases by key terminology were completed. In addition, data were compiled
from current financial and trade information and government sources.
ANALYST' s CREDENTIALS
Shalini Shahani Dewan holds a masters degree in pharmaceutical chemistry.
Among the research topics she has covered are studies on compounds of
potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid.
Shahani was awarded a gold medal by the prime minister of India for her work
and has worked with top companies in India and in the U.S. Some of her other
reports with BCC include Reagents of Chromatography; Spectroscopy: An Enduring
Market; Advanced Drug Delivery Systems; Orthopedic Drugs, Implants and
Devices; Imaging Reagents; Contract Manufacturing, Research and Packaging; The
Dynamic Media, Sera and Reagent market in Biotechnology; Opportunities in
Chiral Technology; Behavioral and Emotional Disorders in Children and
Adolescents; and Pharmaceutical Regulatory Industry, and many more.
Table of Contents
Hormone Replacement Therapies and Other Hormone Therapies: Global Markets
Chapter-1: SUMMARY
- SUMMARY TABLE SALES FOR THE HORMONE REPLACEMENT AND OTHER THERAPIES,
THROUGH 2013 ($ MILLIONS)
- SUMMARY FIGURE SALES FOR THE HORMONE REPLACEMENT AND OTHER THERAPIES,
2006-2013 ($ MILLIONS)
Chapter-2: OVERVIEW
- HORMONES
- DEFINITIONS
- Hormone
- Peptide
- Metabolism
- INTRODUCTION
- Classification of Hormones
- Anatomical Source of the Hormone
- Hypothalamic Hormones
- Posterior Pituitary Hormone
- Anterior Pituitary Hormone
- Thyroid Hormones
- Parathyroid Hormones
- Cardiac Hormones
- Adrenal Cortical Hormones
- Adrenal Medullary Hormones
- Kidney Hormones
- Pancreatic Hormones
- Liver Hormones
- Digestive Hormones
- Gonadal Hormones
- Gonadal Hormones (Continued)
- Pineal Hormones
- TABLE 1 ANATOMICAL CLASSIFICATION OF HORMONES
- Chemical Classification
- Peptide Hormones
- Amine hormones
- Steroid Hormones
- TABLE 2 CHEMICAL CLASSIFICATION OF HORMONES
- HORMONE THERAPY
- DEFINITION
Chapter-3: CLASSIFICATION OF HORMONE THERAPY
- ESTROGEN THERAPY
- TABLE 3 DRUG PRODUCTS USED IN ESTROGEN THERAPY
- PROGESTERONE/ESTROGEN THERAPY
- TABLE 4 DRUG PRODUCTS USED IN ESTROGEN/PROGESTERONE COMBINATION THERAPY
- PROGESTERONE THERAPY
- TABLE 5 DRUG PRODUCTS USED IN PROGESTERONE THERAPY
- RECOMBINANT GROWTH HORMONE THERAPY
- TABLE 6 DRUG PRODUCTS USED IN RECOMBINANT GROWTH HORMONES
- THYROID HORMONE THERAPY
- TABLE 7 DRUG PRODUCTS USED IN THYROID HORMONE THERAPY
- TABLE 7 (CONTINUED)
- TESTOSTERONE REPLACEMENT THERAPY
- TABLE 8 DRUG PRODUCTS USED IN TESTOSTERONE REPLACEMENT THERAPY
- SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)
- TABLE 9 DRUG PRODUCTS USED IN SELECTIVE ESTROGEN RECEPTOR MODULATORS
- ANTIESTROGEN THERAPY
- TABLE 10 DRUG PRODUCTS USED IN ANTIESTROGENS
- ANTIANDROGEN THERAPY
- TABLE 11 DRUG PRODUCTS USED IN ANTIANDROGEN THERAPY
- AROMATASE INHIBITOR THERAPY
- TABLE 12 DRUG PRODUCTS USED IN AROMATASE INHIBITOR THERAPY
- LUTEINIZING HORMONE-RELEASING HORMONE
- TABLE 13 DRUG PRODUCTS USED AS LUTEINIZING HORMONE-RELEASING HORMONE (LH RH)
Chapter-4: HORMONE THERAPY IN VARIOUS CONDITIONS
- MENOPAUSE
- MENOPAUSE AND HORMONE THERAPY
- OSTEOPOROSIS
- OSTEOPOROSIS AND HORMONE THERAPY
- CANCER
- CANCER AND HORMONE THERAPY
- GROWTH HORMONE DEFICIENCIES
- GROWTH HORMONE DEFICIENCY AND HORMONE THERAPY
- TURNER' S SYNDROME
- TURNER' S SYNDROME AND HORMONE THERAPY
- KLINEFELTER SYNDROME
- KLINEFELTER SYNDROME AND HORMONE THERAPY
- THYROID HORMONE DISORDER: HYPOTHYROIDISM
- HYPOTHYROIDISM AND HORMONE THERAPY
- MALE HYPOGONADISM
- MALE HYPOGONADISM AND HORMONE THERAPY
- NOONAN SYNDROME
- NOONAN SYNDROME AND HORMONE THERAPY
- SHORT BOWEL SYNDROME (SBS)
- SBS AND HORMONE THERAPY
- PRADER-WILLI SYNDROME
- PRADER-WILLI SYNDROME AND HORMONE THERAPY
- GOITER
- GOITER AND HORMONE THERAPY
Chapter-5: REGULATORY ISSUES
- NEW DRUG APPROVALS
- TABLE 14 HORMONE THERAPY DRUGS APPROVED BY FDA (2005 TO JUNE 2008)
- ALL TYPES OF APPROVALS
- TABLE 15 HORMONE THERAPY ALL TYPES OF APPROVALS BY FDA (2005 TO JUNE 2008)
- TABLE 15 (CONTINUED)
- TABLE 15 (CONTINUED)
- NEW DRUG APPLICATIONS
- TABLE 16 NEW DRUG APPLICATIONS (2005 TO JUNE 2008)
- RECALLS AND SAFETY ALERTS
- TABLE 17 RECALLS AND SAFETY ALERTS (2005 TO JUNE 2008)
Chapter-6: INDUSTRY STRUCTURE
- ESTROGEN REPLACEMENT THERAPY
- ESTROGEN (ALONE)
- TABLE 18 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ESTROGEN (ALONE) THERAPY, 2007 (%)
- FIGURE 1 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ESTROGEN REPLACEMENT THERAPY, 2007 (%)
- ESTROGEN/PROGESTERONE
- TABLE 19 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR COMBINATION (ESTROGEN/PROGESTERONE) THERAPY, 2007 (%)
- FIGURE 2 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR COMBINATION (ESTROGEN/PROGESTERONE) THERAPY, 2007 (%)
- RECOMBINANT GROWTH HORMONE THERAPY
- TABLE 20 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR RECOMBINANT GROWTH HORMONE THERAPY, 2007 (%)
- FIGURE 3 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR RECOMBINANT GROWTH HORMONE THERAPY, 2007 (%)
- THYROID HORMONE THERAPY
- TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR THYROID HORMONE THERAPY, 2007 (%)
- FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR THYROID HORMONE THERAPY, 2007 (%)
- TESTOSTERONE HORMONE THERAPY
- TABLE 22 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TESTOSTERONE HORMONE THERAPY, 2007 (%)
- FIGURE 5 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TESTOSTERONE HORMONE THERAPY, 2007 (%)
- ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM)
- TABLE 23 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2007 (%)
- FIGURE 6 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2007 (%)
- ANTIANDROGENS
- TABLE 24 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)
- FIGURE 7 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)
- AROMATASE INHIBITORS
- TABLE 25 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)
- FIGURE 8 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)
- LUTEINIZING HORMONE RELEASING HORMONE (LHRH) AGONISTS
- TABLE 26 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH RH AGONISTS, 2007 (%)
- FIGURE 9 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH RH AGONISTS, 2007 (%)
Chapter-7: DEMAND AND USE
- KEY MARKET RESTRAINTS
- COMPETITION
- PATENT EXPIRATION
- TABLE 27 SIGNIFICANT PATENT EXPIRIES
- COST OF HRT DRUGS
- LOW AWARENESS
- KEY MARKET DRIVERS
- NEW DRUG DELIVERY TECHNOLOGIES
- GROWING AWARENESS
- AGING OF THE POPULATION
- RETURNING CONFIDENCE IN HRT
- BENEFITS OF HRT OVER NON-HORMONAL DRUGS
- LIFE EXPECTANCY
- DTC (DIRECT TO CONSUMER) ADVERTISING
- STRATEGIES OF MANUFACTURERS
- Strategies of Manufacturers (Continued)
Chapter-8: MARKET ANALYSIS
- MARKET SIZE
- TABLE 28 WORLDWIDE SALES OF HORMONE THERAPIES, THROUGH 2013 ($ MILLIONS)
- FIGURE 10 WORLDWIDE SALES OF HORMONE THERAPIES, 2006-2013 ($ MILLIONS)
- TABLE 29 WORLDWIDE SHARE OF HORMONE THERAPIES, 2007
- FIGURE 11 WORLDWIDE SHARE OF HORMONE THERAPIES, 2007 (%)
- ESTROGEN REPLACEMENT THERAPY
- Market Outlook
- ESTROGEN
- Market Size
- TABLE 30 GLOBAL SALES OF ESTROGEN (ALONE) THERAPY, THROUGH 2013 ($ MILLIONS)
- FIGURE 12 WORLDWIDE SALES OF ESTROGEN (ALONE) THERAPY, 2006-2013 ($ MILLIONS)
- COMBINATION THERAPY (ESTROGEN/ PROGESTERONE)
- Market Size
- TABLE 31 GLOBAL SALES OF COMBINATION THERAPY (ESTROGEN/PROGESTERONE), THROUGH 2013 ($ MILLIONS)
- FIGURE 13 WORLDWIDE SALES OF COMBINATION THERAPY (ESTROGEN/PROGESTERONE), 2006-2013 ($ MILLIONS)
- RECOMBINANT GROWTH HORMONE THERAPY
- Market Outlook
- Market Size
- TABLE 32 GLOBAL SALES OF RECOBINANT GROWTH HORMONE THERAPY THROUGH 2013 ($ MILLIONS)
- FIGURE 14 WORLDWIDE SALES OF RECOMBINANT GROWTH HORMONE THERAPY, 2006-2013 ($ MILLIONS)
- THYROID HORMONE THERAPY
- Market Outlook
- Market Size
- TABLE 33 GLOBAL SALES OF THYROID HORMONE THERAPY, THROUGH 2013 ($ MILLIONS)
- FIGURE 15 WORLDWIDE SALES OF THYROID HORMONE THERAPY, 2006-2013 ($ MILLIONS)
- TESTOSTERONE HORMONE THERAPY
- Market Outlook
- Market Size
- TABLE 34 GLOBAL SALES OF TESTOSTERONE HORMONE THERAPY, THROUGH 2013 ($ MILLIONS)
- FIGURE 16 WORLDWIDE SALES OF TESTOSTERONE HORMONE THERAPY, 2006-2013 ($ MILLIONS)
- ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM)
- Market Outlook
- Market Size
- TABLE 35 GLOBAL SALES OF ANTIESTROGEN AND SELECTIVE ESTROGEN RECPTOR MODULATORS, THROUGH 2013 ($ MILLIONS)
- FIGURE 17 WORLDWIDE SALES OF ANTIESTROGEN AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2006-2013 ($ MILLIONS)
- ANTIANDROGEN THERAPY
- Market Outlook
- Market Size
- TABLE 36 GLOBAL SALES OF ANTIANDROGEN THERAPY, THROUGH 2013 ($ MILLIONS)
- FIGURE 18 WORLDWIDE SALES OF ANTIANDROGEN THERAPY, 2006-2013 ($ MILLIONS)
- AROMATASE INHIBITORS
- Market Outlook
- Market Size
- TABLE 37 GLOBAL SALES OF AROMATASE INHIBITORS, THROUGH 2013 ($ MILLIONS)
- FIGURE 19 WORLDWIDE SALES OF AROMATASE INHIBITORS, 2006-2013 ($ MILLIONS)
- LUTEINIZING HORMONE-RELEASING HORMONE (LH RH) AGONISTS
- Market Outlook
- Market Size
- TABLE 38 GLOBAL SALES OF LH RH AGONISTS, THROUGH 2013 ($ MILLIONS)
- FIGURE 20 WORLDWIDE SALES OF LH RH AGONIST, 2006-2013 ($ MILLIONS)
- New Developments
- TABLE 39 CLINICAL TRIALS IN THE ESTROGEN REPLACEMENT THERAPY
- TABLE 39 (CONTINUED)
- TABLE 40 CLINICAL TRIALS IN THE PROGESTEROEN THERAPY
- TABLE 40 (CONTINUED)
- TABLE 41 CLINICAL TRIALS IN THYROID HORMONE THERAPY
- TABLE 42 CLINICAL TRIALS IN TESTOSTERONE REPLACEMENT THERAPY
- TABLE 42 (CONTINUED)
- TABLE 43 CLINICAL TRIALS IN RECOMBINANT GROWTH HORMONE
- TABLE 43 (CONTINUED)
- TABLE 44 CLINICAL TRIALS IN ANTIESTROGEN THERAPY
- TABLE 44 (CONTINUED)
- TABLE 44 (CONTINUED)
- TABLE 45 CLINICAL TRIALS IN ESTROGEN RECEPTOR MODULATORS
- TABLE 46 CLINICAL TRIALS IN ANTIANDROGEN THERAPY
- TABLE 47 CLINICAL TRIALS IN AROMATASE INHIBITORS
- TABLE 48 CLINICAL TRIALS IN LH RH AGONISTS
Chapter-9: MARKET BY DISEASE TYPE
- TABLE 49 GLOBAL SALES OF HORMONE THERAPY BY TYPE OF DISEASE, THROUGH 2013 ($ MILLIONS)
- FIGURE 21 GLOBAL SALES OF HORMONE THERAPY BY TYPE OF DISEASE, 2006-2013 ($ MILLIONS)
- TABLE 50 MARKET SHARE OF VARIOUS TYPES OF DISEASES, 2007 (%)
- FIGURE 22 MARKET SHARE OF VARIOUS TYPES OF DISEASES, 2007 (%)
- MENOPAUSE
- TABLE 51 GLOBAL SALES OF HRT IN MENOPAUSE MARKET, THROUGH 2013 ($ MILLIONS)
- FIGURE 23 GLOBAL SALES OF HRT IN MENOPAUSE MARKET, 2006-2013 ($ MILLIONS)
- OSTEOPOROSIS
- TABLE 52 GLOBAL SALES OF HRT IN OSTEOPOROSIS MARKET, THROUGH 2013 ($ MILLIONS)
- FIGURE 24 GLOBAL SALES OF HRT IN OSTEOPOROSIS MARKET, 2006-2013 ($ MILLIONS)
- HYPOTHYROIDISM
- TABLE 53 GLOBAL SALES OF HRT IN HYPOTHYROID MARKET, THROUGH 2013 ($ MILLIONS)
- FIGURE 25 GLOBAL SALES OF HRT IN HYPOTHYROID MARKET, 2006-2013 ($ MILLIONS)
- MALE HYPOGONADISM
- TABLE 54 GLOBAL SALES OF HRT IN THE MALE HYPOGONADISM MARKET, THROUGH 2013 ($ MILLIONS)
- FIGURE 26 GLOBAL SALES OF HRT IN THE MALE HYPOGINADISM MARKET, 2006-2013 ($ MILLIONS)
- KLINEFELTER SYNDROME
- TABLE 55 GLOBAL SALES OF HRT IN KLINEFELTER SYNDROME MARKET, THROUGH 2013 ($ MILLIONS)
- FIGURE 27 GLOBAL SALES OF HRT IN KLINEFELTER SYNDROME MARKET, 2006-2013 ($ MILLIONS)
- TURNER' S SYNDROME
- TABLE 56 GLOBAL SALES OF HRT IN TURNER' S SYNDROME MARKET, THROUGH 2013 ($ MILLIONS)
- FIGURE 28 GLOBAL SALES OF HRT IN TURNER' S SYNDROME MARKET, 2006-2013 ($ MILLIONS)
- GROWTH HORMONE DEFICIENCY
- TABLE 57 GLOBAL SALES OF HRT IN GROWTH HORMONE DEFICIENCY MARKET, THROUGH 2013 ($ MILLIONS)
- FIGURE 29 GLOBAL SALES OF HRT IN GROWTH HORMONE DEFECIENCY MARKET, 2006-2013 ($ MILLIONS)
- CANCER
- TABLE 58 GLOBAL SALES OF HRT IN CANCER MARKE, THROUGH 2013 ($ MILLIONS)
- FIGURE 30 GLOBAL SALES OF HRT IN CANCER MARKET, 2006-2013 ($ MILLIONS)
Chapter-10: PATENT ANALYSIS
- TOTAL PATENTS
- PATENTS BY YEAR
- TABLE 59 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005 - 2008
- FIGURE 31 NUMBER OF PATENTS, 2005-2008
- PATENTS BY TYPE
- TABLE 60 NUMBER OF PATENTS BY TYPE, 2005-2008
- FIGURE 32 NUMBER OF PATENTS BY TYPE, 2005-2008
- FIGURE 33 NUMBER OF PATENTS, SHARE BY TYPE OF HORMONE, 2005-2008 (%)
- FIGURE 33 (CONTINUED)
- PATENTS BY COUNTRY
- TABLE 61 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008
- FIGURE 34 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008
- PATENTS BY COMPANY
- TABLE 62 NUMBER OF PATENTS BY COMPANY, 2005-2008
- FIGURE 35 NUMBER OF PATENTS BY COMPANY, 2005-2008
- PATENTS BY ASSIGNEE
- TABLE 63 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2005 - 2008
- FIGURE 36 NUMBER OF PATENTS BY ASSIGNEE, 2005 - 2008
Chapter-11: CURRENT AND FUTURE HORMONE REPLACEMENT THERAPY AND “OTHER” HORMONE THERAPY MARKET 2 $
- TABLE 64 LEADING BRANDED DRUGS IN VARIOUS HORMONE THERAPIES
- CURRENT AND FUTURE HORMONE.....(CONTINUED)
Chapter-12: COMPANY PROFILES
- ABBOTT LABORATORIES INC.
- ACRUX LIMITED
- ASCEND THERAPEUTICS
- ASTRAZENECA PLC
- AUXILIUM PHARMACEUTICALS, INC.
- BARR PHARMACEUTICALS, INC.
- BAYER SCHERING PHARMA AG
- BIOSANTE PHARMACEUTICALS
- CANGENE CORPORATION
- COLUMBIA LABORATORIES, INC.
- ELI LILLY & CO.
- EMD SERONO, INC.
- FERRING PHARMACEUTICALS
- GALEN LTD.
- GENENTECH
- GENESCIENCE PHARMACEUTICALS INC.
- IMPAX LABORATORIES, INC.
- INDEVUS PHARMECEUTICALS, INC.
- IPSEN SA
- JHP PHARMACEUTICALS
- KING PHARMACEUTICALS, INC.
- KV PHARMACEUTICALS
- MYLAN, INC.
- NOVARTIS
- NOVO NORDISK
- NYCOMED U.S.
- ORION CORPORATION
- PADDOCK LABORATORIES, INC.
- PAR PHARMACEUTICAL COMPANIES, INC.
- PFIZER INC.
- SANOFI AVENTIS
- SOLVAY PHARMACEUTICALS
- SYNERX PHARMA
- UNIGENE LABORATORIES, INC.
- UNIMED PHARMACEUTICALS, INC.
- WARNER CHILCOTT
- WATSON LABS
- WYETH
Chapter-13: APPENDIX
- ABBREVIATIONS
- ABBREVIATIONS (CONTINUED)
|
 |
